MedDataX Logo

Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

NCT ID: NCT07342920

Last Updated: 2026-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-15

Study Completion Date

2026-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population.

Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention.

This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Home Monitoring to Predict Exacerbation in Cystic Fibrosis

NCT02416375

Cystic Fibrosis
COMPLETED

Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis

NCT00850551

Cystic Fibrosis
COMPLETED NA

Clinical Effort Against Smoke Exposure in Cystic Fibrosis

NCT04777344

Cystic Fibrosis
COMPLETED NA

Extrapulmonary Effects of Cystic Fibrosis on Physical Activity of Adult Patients.

NCT01848392

Cystic Fibrosis
COMPLETED

Prevalence and Impact of Depression and Anxiety in Cystic Fibrosis

NCT03424486

Cystic Fibrosis
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥ 18 years old)
* With confirmed cystic fibrosis
* Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center

Exclusion Criteria

* Patients who have undergone a double lung transplant for cystic fibrosis.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Pneumologie - CHU de Strasbourg - France

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Romain Kessler, MD, PhD

Role: CONTACT

[email protected]
33 3 69 55 03 77

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Romain Kessler, MD, PhD

Role: primary

[email protected]
33 3 69 55 03 77

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9813

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Non-respiratory Comorbidities Observed in Pulmonary French Transplant Patients With Cystic Fibrosis
NCT03357913 COMPLETED
Analysis of Remote Monitoring/Virtual Clinic Data in Adult Patients With Cystic Fibrosis (Project Breathe)
NCT06222905 ACTIVE_NOT_RECRUITING
Tracking CF Lung Disease Through the Early Years: Utility of the LCI
NCT03138772 COMPLETED
Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients
NCT03736096 COMPLETED
Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis
NCT06507956 RECRUITING
The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective
NCT01306279 COMPLETED
COVID-19 Antibody Responses in Cystic Fibrosis
NCT05614336 ACTIVE_NOT_RECRUITING NA
Costs of Care and Adherence to Treatment for Cystic Fibrosis
NCT02832479 COMPLETED
Microbial Community Composition and Dynamics in Lungs of Cystic Fibrosis Sibling Pairs
NCT00590330 COMPLETED
Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis
NCT00750932 COMPLETED
MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique
NCT03304028 TERMINATED NA
Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.
NCT03312075 UNKNOWN
Sputum Purulence as a Predictor of Cystic Fibrosis Exacerbations: a Prospective Cohort Trial.
NCT02309229 COMPLETED
Cystic Fibrosis Adherence Study
NCT04217889 COMPLETED
Improvement of Aerobic Capacity in Cystic Fibrosis Patients With a One-year Home Training Period
NCT00792194 COMPLETED NA
The Use of Breath Volatile Organic Compounds in Early Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis
NCT05944367 COMPLETED
Covid-19 Antibody Responses in Cystic Fibrosis
NCT05012306 ACTIVE_NOT_RECRUITING
Relationship Between Health Literacy and Physical Activity in Adult Patients With Cystic Fibrosis
NCT05963503 RECRUITING
Evaluation of Patient Access to People With Cystic Fibrosis (CF) and Healthcare Professionals
NCT06122025 COMPLETED NA
Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects
NCT06339450 NOT_YET_RECRUITING NA
Timing of Hypertonic Saline Inhalation Relative to Airways Clearance in Cystic Fibrosis
NCT01753869 TERMINATED NA
Effects of a Partially Supervised Conditioning Program in CF
NCT01744561 COMPLETED NA
Diet, Physical Activity and Glucose Tolerance in Cystic Fibrosis. Exploratory Study.
NCT04249466 COMPLETED
Improving Therapeutic Adherence With a Co-constructed Program Involving Both Patients and Health Care Professionals
NCT03226795 UNKNOWN NA
Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience
NCT01013896 COMPLETED NA